Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,050 JPY | +0.16% | +0.66% | -6.73% |
Apr. 25 | Hidehiro Imatsu named president of Goldman Sachs Japan | RE |
Mar. 21 | Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. | CI |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company shows low valuation levels, with an enterprise value at 0.44 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm trades with high earnings multiples: 24.62 times its 2024 earnings per share.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.73% | 691M | - | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
+11.88% | 216B | B- | ||
-0.78% | 219B | A+ | ||
+5.90% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4534 Stock
- Ratings Mochida Pharmaceutical Co., Ltd.